SavedAdd your journal

Journals / Turkish Journal of Immunology / 2017 / Cilt: 5 - Sayı: 3

Interleukin-2 Immunotherapy for Advanced Cancer

İleri evre kanser tedavisinde interlökin-2 immünoterapisi

Dilara SAHİN
Onur BOYMAN
Pages
61–68
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, we review the use of IL-2 for cancer immunotherapy, and discussthe preclinical and translational aspects of IL-2 complexes and their potential for the treatment of advanced cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Interleukin-2 (IL-2) was the first approved immunotherapy to show efficacy in advanced cancer. 13–20% of patientswith metastatic renal cell carcinoma and metastatic melanoma receiving high-dose IL-2 treatment showed objectiveclinical responses, some enduring for up to 20 years and more.
📊
Key Findings & Data:However, the use of IL-2 immunotherapy was hamperedby the short in vivo half-life of IL-2, dose-dependent toxicity and stimulation of immunosuppressive regulatory Tcells.
💡
Conclusion & Impact:In this article, we review the use of IL-2 for cancer immunotherapy, and discussthe preclinical and translational aspects of IL-2 complexes and their potential for the treatment of advanced cancer.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Interleukin-2 (IL-2) was the first approved immunotherapy to show efficacy in advanced cancer. 13–20% of patientswith metastatic renal cell carcinoma and metastatic melanoma receiving high-dose IL-2 treatment showed objectiveclinical responses, some enduring for up to 20 years and more. However, the use of IL-2 immunotherapy was hamperedby the short in vivo half-life of IL-2, dose-dependent toxicity and stimulation of immunosuppressive regulatory Tcells. Recent efforts have explored the biology of IL-2 and its receptors to generate improved IL-2 formulations. SuchIL-2 formulations provide targeted and potent stimulation of selected lymphocyte subsets, and they include IL-2/anti-IL-2 monoclonal antibody complexes (briefly, IL-2 complexes), IL-2 muteins, and versions of IL-2 bound topolyethylene glycol or other molecules. In this article, we review the use of IL-2 for cancer immunotherapy, and discussthe preclinical and translational aspects of IL-2 complexes and their potential for the treatment of advanced cancer.

Özet

Interlökin-2 (IL-2), ileri evre kanser vakalarında etkisi kanıtlanan ve tedavi için onaylanan ilk immünoterapi stratejisidir. Yüksek doz IL-2 tedavisi gören metastatik renal hücreli karsinom ve metastatik melanom hasarının %13–20’sinde tedaviye objektif yanıt alınmış ve hastaların bir bölümünde hastalıksız sağkalım 20 yılı aşmıştır. Ancak, IL-2 immünoterapisinin kullanımı, in vivo yarı-ömrünün kısa olması, doza bağlı toksisite ve immünosupresif düzenleyici T hücrelerinin stimülasyonu nedeniyle yaygınlaşmamıştır. IL-2 ve IL-2 reseptörlerindeki ilerleyen güncel çalışmalar sonucunda, geliştirilmiş IL-2 formülasyonları üretilmiştir. Bu formülasyonlar, IL-2/anti-IL-2 monoklonal antikor kompleksleri (kısaca, IL-2 kompleksleri), IL-2 muteinleri ve IL-2’nin polietilen glikol ve benzeri moleküllere bağlanmasını içermekte ve seçilmiş lenfosit alt-gruplarının selektif ve güçlü stimülasyonunu sağlamaktadır. Bu makalede, IL-2’nin kanser immünoterapisindeki rolü özetlenmekte ve IL-2 komplekslerinin klinik-öncesi çalışmaları ile kanser tedavisindeki potansiyeli tartışılmaktadır.

🔖

Cite This Article

SAHİN, D., BOYMAN, O. (2022). Interleukin-2 Immunotherapy for Advanced Cancer. Turkish Journal of Immunology, Cilt: 5 - Sayı: 3, 61–68. https://ajindex.com/articles/607239

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010;33:153–65. doi: 10.1016/j.immuni.2010.08.004 Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012;12:180–90. doi: 10.1038/nri3156 Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013;38:13–25. doi: 10.1016/j.immuni.2013.01.004 Yui MA, Hernandez-Hoyos G, Rothenberg EV. A new regulatory region of the IL-2 locus that confers position-independent transgene expression. J Immunol 2001;166:1730–9.
  2. Granucci F, Vizzardelli C, Pavelka N, Feau S, Persico M, Virzi E, et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol 2001;2:882–8. doi: 10.1038/ni0901-882 Hershko AY, Suzuki R, Charles N, Alvarez-Errico D, Sargent JL, Laurence A, et al. Mast cell interleukin-2 production contributes to suppression of chronic allergic dermatitis. Immunity 2011;35:562–71. doi: 10.1016/j.immuni.2011.07.013 Amado IF, Berges J, Luther RJ, Mailhe MP, Garcia S, Bandeira A, et al. IL-2 coordinates IL-2-producing and regulatory T cell interplay. J Exp Med 2013;210:2707–20. doi: 10.1084/ jem.20122759 Martins GA, Cimmino L, Liao J, Magnusdottir E, Calame K. Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival. J Exp Med 2008;205:1959–65. doi: 10.1084/jem.20080526 Kallies A, Xin A, Belz GT, Nutt SL. Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity 2009;31:283–95. doi: 10.1016/j. immuni.2009.06.021 Rutishauser RL, Martins GA, Kalachikov S, Chandele A, Parish IA, Meffre E, et al. Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity 2009;31:296–308. doi: 10.1016/j.immuni.2009.05.014 Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: Biology, Design and Application. Trends Immunol 2015;36:763– 77. doi: 10.1016/j.it.2015.10.003 Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993;73:5–8.
  3. Hemar A, Subtil A, Lieb M, Morelon E, Hellio R, Dautry-Varsat A. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains. J Cell Biol 1995;129:55–64